Anti-SARS-CoV-2 Spike S1 (RBD) Neutralizing Antibody (V3S-0623-XY114) (CAT#: V3S-0623-XY114)

Send Inquiry
  • fig1

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description The antibody CV07-250 is a human mAb specific for SARS-CoV-2 Spike S1 protein. The strongest neutralizing mAb reduced ACE2 binding to the RBD to 58.3%. The binding mode of antibody to the RBD is unusual in that it is dominated by the light chain. It uses CDR H1, H3, L1, and L3 and framework region 3 (LFR3) for RBD interaction. It (IC50 = 3.5 ng/mL) had 33 SHMs (17/16 on the heavy and light chain, respectively) and strongly reduced ACE2 binding and showed no binding to murine tissue.
Clonality Monoclonal
Host Species Human
Target Species SARS-CoV-2
Epitope Receptor-binding domain (RBD)
Isotype IgG1

Property

Expression Species HEK293F or CHO cell line
Conjugation Unconjugated
Purity >95%
Endotoxin <1 EU/mg
Form Liquid
Purification Protein A purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics.

Applications

Application ELISA, Neut
Application Notes The IC50 value of CV07-250 is 3.5 ng/mL.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Western Blot Protocol

Target

Target SARS-CoV-2
Alternative Name Severe acute respiratory syndrome coronavirus 2
Research Area Coronavirus Disease 2019
Related Disease Coronavirus Disease 2019
For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
ISO 9001 Certified - Creative Biolabs Quality Management System.
Online Inquiry